A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells

Clinical and Experimental Immunology

Volumn 178, Issue 3, 2014, Pages 470-482

  Lopez Granados, E ^a,b,e   Stacey, M ^a,b   Kienzler, A K ^b   Sierro, S ^a   Willberg, C B ^b   Fox, C P ^c   Rigaud, S ^d   Long, H M ^c   Hislop, A D ^c   Rickinson, A B ^c   Patel, S ^a,b   Latour, S ^d   Klenerman, P ^a   Chapel, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d INSERM   (France)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cytotoxic T cells; Immunodeficiency diseases; T cells; Viral

Indexed keywords

GAMMA INTERFERON; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

BIOSYNTHESIS; CELL CULTURE; EPSTEIN BARR VIRUS; GENETICS; HAPLOTYPE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MUTATION; T LYMPHOCYTE; VIRUS LOAD;

CELLS, CULTURED; HAPLOTYPES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MUTATION; T-LYMPHOCYTES; VIRAL LOAD; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84908669884     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12427     Document Type: Article

References (37)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-768.
2. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3:801-812.
3. Callan MF. The immune response to Epstein-Barr virus. Microbes Infect 2004; 6:937-945.
4. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25:587-617.
5. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE etal., eds. Fields virology, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:2575-2627.
6. Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004; 70:1279-1287.
7. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005; 203:180-199.
8. Parolini S, Bottino C, Falco M etal. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000; 192:337-346.
9. Bottino C, Falco M, Parolini S etal. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001; 194:235-246.
10. Sharifi R, Sinclair JC, Gilmour KC etal. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 2004; 103:3821-3827.
11. Dupre L, Andolfi G, Tangye SG etal. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005; 105:4383-4389.
12. Rigaud S, Fondaneche MC, Lambert N etal. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444:110-114.
13. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-410.
14. Rigaud S, Lopez-Granados E, Sibéril S etal. Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG. Blood 2011; 118:252-261.
15. Aguilar C, Lenoir C, Lambert N etal. XIAP deficiency is associated with severe Crohn's disease and defective NOD2 function. J Allergy Clin Immunol 2014; in press.
16. Speckmann C, Lehmberg K, Albert MH etal. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013; 149:133-141.
17. Semmo N, Krashias G, Willberg C, Klenerman P. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J Viral Hepat 2007; 14:492-502.
18. Betts MR, Brenchley JM, Price DA etal. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
19. Junying J, Herrmann K, Davies G etal. Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. Virology 2003; 306:236-243.
20. Ressing ME, Keating SE, van Leeuwen D etal. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol 2005; 174:6829-6838.
21. Yang X, Kanegane H, Nishidam N etal. Clinical and genetic characteristics of XIAP deficiency in Japan. J Clin Immunol 2012; 32:411-420.
22. Pachlopnik Schmid J, Canioni D, Moshous D etal. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011; 117:1522-1529.
23. Amyes E, Hatton C, Montamat-Sicotte D etal. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003; 198:903-911.
24. Karrer U, Sierro S, Wagner M etal. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol 2003; 170:2022-2029.
25. Bihl F, Frahm N, Di Giammarino L etal. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176:4094-4101.
26. Fafi-Kremer S, Morand P, Brion JP etal. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis 2005; 191:985-989.
27. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004; 104:478-486.
28. Ortolani C, Forti E, Radin E, Cibin R, Cossarizza A. Cytofluorimetric identification of two populations of double positive (CD4+, CD8+) T lymphocytes in human peripheral blood. Biochem Biophys Res Commun 1993; 191:601-609.
29. Landais E, Saulquin X, Scotet E etal. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 2004; 103:1408-1416.
30. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 2006; 203:995-1006.
31. Heller KN, Gurer C, Munz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 2006; 203:805-808.
32. Marsh R, Madden L, Kitchen BJ etal. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010; 116:1079-1082.
33. Rumble J, Oetjen KA, Stein PL, Schwartzberg PL, Moore BB, Duckett CS. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell Immunol 2009; 259:82-89.
34. Wang S, Rowe M, Lundgren E. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996; 56:4610-4613.
35. Chene A, Donati D, Guerreiro-Cacais AO etal. A molecular link between malaria and Epstein-Barr virus reactivation. PLOS Pathog 2007; 3:e80.
36. Younesi V, Shirazi FG, Memarian A, Amanzadeh A, Jeddi-Tehrani M, Shokri F. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay. Cytotechnology 2014; 66:95-105.
37. Lin Q, Rohrer J, Allen RC etal. A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome. J Clin Invest 1996; 97:196-201.